利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.073 秒)

    Method and Kit for the Prognosis of Mantle Cell Lymphoma
    3.
    发明申请
    Method and Kit for the Prognosis of Mantle Cell Lymphoma 审中-公开
    地套细胞淋巴瘤预后的方法和试剂盒

    公开(公告)号：US20120225432A1

    公开(公告)日：2012-09-06

    申请号：US13387658

    申请日：2010-07-30

    申请人： Elias Campo Guerri ,  Olga Salamero Garcia ,  Verònica Fernàndez Pascual ,  Pedro Jares Gerboles ,  Armando López Guillermo

    发明人： Elias Campo Guerri ,  Olga Salamero Garcia ,  Verònica Fernàndez Pascual ,  Pedro Jares Gerboles ,  Armando López Guillermo

    IPC分类号： C12Q1/68 ,  G01N33/53

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118

    摘要： The method and the kit are useful as tools for classifying a patient diagnosed with mantle cell lymphoma into the category of: indolent or conventional. The method comprises: a) providing a sample from a patient suffering from mantle cell lymphoma; b) determining the level of expression of at least one gene selected from the group consisting of: RNGTT, HDGFRP3, FARP1, HMGB3, LGALS3BP, PON2, CDK2AP1, DBN1, CNR1, CNN3, SOX11, SETMAR and CSNK1E in said sample; and c) comparing the level of expression of each of the measured genes with respect to the level of expression of the same genes in a control sample; wherein the absence of expression or the underexpression of said genes with respect to the same genes in said control sample is indicative of the indolent clinical course of the MCL.

    摘要翻译： 该方法和试剂盒可用作将诊断为外套细胞淋巴瘤的患者分类为无痛或常规的工具。 该方法包括：a）从患有外套细胞淋巴瘤的患者提供样品; b）确定所述样品中选自RNGTT，HDGFRP3，FARP1，HMGB3，LGALS3BP，PON2，CDK2AP1，DBN1，CNR1，CNN3，SOX11，SETMAR和CSNK1E中的至少一种基因的表达水平; 和c）比较对照样品中每个测量基因的表达水平与相同基因的表达水平; 其中相对于所述对照样品中相同基因的所述基因的表达缺失或低表达指示MCL的无痛临床病程。